Overall cumulative incidence of confirmed MR^4.5 and Stable MR^4.5 after 8 years of imatinib therapy. (A) MR^4.5 and (B) Stable MR^4.5. Of the patients with at least 24 months of follow-up after MR^4.5, 64% had continuous, undetectable BCR-ABL1.